⌕
Maravai LifeSciences Holdings · MRVI · Nasdaq
Tenet 29 · Weak
Compare
$7.28−1.62%At closeTenet 29 · Weak
$7.28−0.12 (−1.62%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Maravai LifeSciences Holdings (MRVI) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

4 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 79% below its peak, net margin −70.4%.
The four lines that matter · FY21–FY25
Revenue ($M)▼28.3%
185.7
FY21→FY25CAGR −30.6%/yr
Net income ($M)▲9.7%
−130.8
one-off year: see footnoteCAGR —
Free cash flow ($M)▼218.7%
−70.7
FY21→FY25CAGR —
Diluted EPS▲14.3%
−0.90
buyback-liftedCAGR —
What the receipts whisper · what a headline number hides
Share count
−44.0%

257.8mn → 144.4mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.

Capex
$13.1M

−55.7% YoY in FY25 · 7.1% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)185.7Revenue−151.8COGS34.0Gross profit−17.4R&D−145.1SG&A−215.3Op income84.5Tax & other−130.8Net income

-70¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
705335180%sector median net margin ~3%FY21FY25

Net margin -70.4% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
212,996.0185,743.0259,185.0288,945.0883,001.0799,240.0▼28.3%−30.6%
Cost of revenue
129,611.0151,753.0150,876.0148,743.0168,957.0140,561.0▲0.6%+1.9%
Gross profit
83,385.033,990.0108,309.0140,202.0—A—A▼68.6%−50.8%
Research & development
14,769.017,402.019,221.017,280.018,369.015,219.0▼9.5%+3.4%
Selling, general & admin
123,047.0145,118.0161,771.0151,390.0129,259.0100,064.0▼10.3%+9.7%
Total operating expenses
180,046.0249,256.0343,926.0171,850.0139,828.0104,034.0▼27.5%+24.4%
Operating incomefeeds ROC rank
−96,661.0−215,266.0−235,617.0−31,648.0574,216.0554,645.0▲8.6%—
Other income, net
−18,753.0−19,708.0−25,865.0649,384.0−22,744.0−23,880.0——
Pretax income
−115,414.0−234,974.0−261,482.0617,736.0551,472.0530,765.0▲10.1%—
Income tax
−391.0−4,212.0−1,860.0756,111.060,809.061,515.0▼126.5%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−65,669.0−130,773.0−144,846.0−119,029.0220,205.0469,250.0▲9.7%—
Per share
Diluted EPSbuyback-sensitive
−0.43−0.90−1.05−0.901.671.56▲14.3%—
Diluted shares (mn)
149.07144.36137.91131.92255.32257.80▲4.7%−13.5%
Margins
Gross margin20th pct in Healthcare
39.1%18.3%41.8%48.5%—A—A▼23.5pp−30.2pp
Operating margin
−45.4%−115.9%−90.9%−11.0%65.0%69.4%▼25.0pp−185.3pp
Net margin19th pct in Healthcare
−30.8%−70.4%−55.9%−41.2%24.9%58.7%▼14.5pp−129.1pp
† TTM = trailing four quarters through 2026-09-30.FY23 effective tax rate was 122% vs a 11% norm for this window, likely a one-time item; see the filing.FY24 effective tax rate was 1% vs a 11% norm for this window, likely a one-time item; see the filing.A Withheld: this year's gross margin is not on the same cost basis as the earlier years.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Maravai LifeSciences Holdings' revenue last fiscal year?

Maravai LifeSciences Holdings reported revenue of $185.7M in fiscal 2025, down 28.3% from fiscal 2024.

What was Maravai LifeSciences Holdings' net income?

Maravai LifeSciences Holdings reported net income of −$130.8M in fiscal 2025, a net margin of −70.4%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.